Skip to main content
Fig. 5 | The Journal of Headache and Pain

Fig. 5

From: Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients

Fig. 5

Percentage of CM patients reporting a headache during a day from Day 1 to 7. Headache in CM patients was defined as those of at least moderate severity. Day 1 is the day of injection of study medications. Fremanezumab is the sum of fremanezumab monthly and fremanezumab quarterly groups. P < 0.05 for difference with placebo from Day 2–7 for fremanezumab

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us